Traders bought shares of Gilead Sciences (NASDAQ:GILD) on weakness during trading on Thursday following insider selling activity. $136.73 million flowed into the stock on the tick-up and $70.89 million flowed out of the stock on the tick-down, for a money net flow of $65.84 million into the stock. Of all companies tracked, Gilead Sciences had the 4th highest net in-flow for the day. Gilead Sciences traded down ($0.58) for the day and closed at $74.82Specifically, Director John Francis Cogan sold 5,833 shares of the stock in a transaction on Friday, March 23rd. The stock was sold at an average price of $75.02, for a total transaction of $437,591.66. Following the transaction, the director now owns 58,452 shares of the company’s stock, valued at approximately $4,385,069.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $73.14, for a total value of $3,657,000.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at approximately $224,376,112.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 426,934 shares of company stock worth $33,847,101. 1.30% of the stock is owned by corporate insiders.
A number of brokerages have weighed in on GILD. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Credit Suisse Group set a $80.00 price target on Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. Leerink Swann reduced their price target on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 7th. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target on the stock in a research note on Monday, February 19th. Finally, Barclays reissued an “overweight” rating and set a $95.00 price target (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $88.61.
The firm has a market capitalization of $98,310.29, a P/E ratio of 8.58, a price-to-earnings-growth ratio of -1.73 and a beta of 1.19. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.70 EPS. research analysts forecast that Gilead Sciences will post 6.21 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.11%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, March 15th. Gilead Sciences’s dividend payout ratio is presently 26.64%.
Hedge funds have recently added to or reduced their stakes in the company. Williams Jones & Associates LLC increased its holdings in Gilead Sciences by 10.4% in the 2nd quarter. Williams Jones & Associates LLC now owns 6,930 shares of the biopharmaceutical company’s stock valued at $491,000 after purchasing an additional 650 shares in the last quarter. Prudential PLC increased its holdings in Gilead Sciences by 5.0% in the 2nd quarter. Prudential PLC now owns 3,525,167 shares of the biopharmaceutical company’s stock valued at $249,512,000 after purchasing an additional 168,200 shares in the last quarter. Sii Investments Inc. WI increased its holdings in Gilead Sciences by 13.3% in the 2nd quarter. Sii Investments Inc. WI now owns 34,727 shares of the biopharmaceutical company’s stock valued at $2,460,000 after purchasing an additional 4,083 shares in the last quarter. San Francisco Sentry Investment Group CA increased its holdings in Gilead Sciences by 9.1% in the 2nd quarter. San Francisco Sentry Investment Group CA now owns 7,094 shares of the biopharmaceutical company’s stock valued at $502,000 after purchasing an additional 593 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in Gilead Sciences by 856.9% in the 2nd quarter. Janus Henderson Group PLC now owns 1,751,194 shares of the biopharmaceutical company’s stock valued at $123,949,000 after purchasing an additional 1,568,191 shares in the last quarter. Institutional investors and hedge funds own 77.91% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Traders Buy Shares of Gilead Sciences (GILD) on Weakness After Insider Selling” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/traders-buy-shares-of-gilead-sciences-gild-on-weakness-after-insider-selling.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.